Year-over-year earnings per share growth for the last twelve months: dermatarx.com (DRMA)

Dermata Corp - graphic logo of issuer DRMA

Dermata Therapeutics (DRMA) is implementing zero-waste substance synthesis, which supports asset dynamics. The GURU.Markets interface displays this chart, where the quarterly earnings per share growth rate is recorded at 65.90, confirming financial stability. Meanwhile, the company adheres to bioethics norms and ESG standards, although a narrow focus on sponge-derived drugs creates high binary risks for the business.

dermatarx.com (DRMA) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/15/2026

dermatarx.com (DRMA) - metric breakdowns and financial figures

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Basic company analysis:Dermata Therapeutics Inc - DRMA
Manufactured product of Dermata Therapeutics

Quarterly earnings per share (EPS) dynamics serve as a leading indicator of financial stability, revealing hidden imbalances between operating expenses and actual returns before they are recorded in financial statements. Analyzing the quarterly EPS growth rate allows for an assessment of the effectiveness of implementing robotic molecule screening and clinical trial data processing automation, which directly contribute to reducing costs for Dermata Therapeutics (DRMA).

Competitor analysis

KRYS: Quarterly EPS earnings growth|APGE - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Arcutis Biotherapeutics, Inc.|Year-over-year earnings per share growth for the last 12 months VCEL (Vericel)|Year-over-year earnings per share growth for the last twelve months Oruka Pharma (ORKA)|Year-over-year net earnings per share change for the last twelve months Sanara MedTech|Quarterly EPS earnings growth DBVT (DBV Technologies SA)|Solesence Inc (SLSN) - Earnings per share growth in annualized terms for the last twelve months|DERM: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months FBRX (Forte Biosciences)|Empro Group (EMPG) - Year-over-year earnings per share growth for the last twelve months|Net earnings per share growth for the trailing year Sol-Gel Technologies Ltd. SLGL|Year-over-year net earnings per share growth for the last 12 months AXIL|Year-over-year net earnings per share growth for the last 12 months Medicus Pharma Ltd. (MDCX)|Quarterly EPS earnings growth VRCA|Year-over-year earnings per share growth rate for the last twelve months HOTH|Year-over-year earnings per share growth for the last twelve months biofrontera-us.com BFRI|Year-over-year earnings per one share growth for the last 12 months VYNE|SNOA - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per one share growth for the last 12 months QNRX (quoinpharma.com)|Azitra (AZTR) - Year-over-year earnings per share growth for the last twelve months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth